Abbott
Key Fundamentals
MidcapPharmaceuticalsHealthcarePrice-based figures as of 13 Oct 2026, 15:29 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,770.70 | 35.13 | 4,24,850 Cr | 5.08 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,285.00 | 84.27 | 2,46,488 Cr | 14.71 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,642.90 | 72.89 | 1,76,601 Cr | 21.00 | 0.82% | 12.16% | 9.06% | 15,391 Cr | 2,156 Cr | |
| ₹1,132.50 | 25.20 | 1,12,967 Cr | 4.17 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹2,059.40 | 101.75 | 1,11,272 Cr | 21.00 | 0.10% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,329.60 | 31.85 | 1,07,413 Cr | 3.12 | 1.00% | 11.21% | 14.88% | 28,786 Cr | 3,356 Cr | |
| ₹1,240.00 | 32.12 | 1,03,500 Cr | 2.72 | 0.67% | 10.87% | 13.94% | 34,555 Cr | 3,184 Cr | |
| ₹2,372.00 | 47.95 | 97,974 Cr | 6.01 | 0.04% | 11.70% | 13.78% | 15,074 Cr | 2,067 Cr | |
| ₹1,684.60 | 26.28 | 96,928 Cr | 2.56 | 0.24% | 9.25% | 13.58% | 35,390 Cr | 3,711 Cr | |
| ₹1,953.60 | 16.15 | 89,336 Cr | 3.98 | 0.92% | 23.79% | 28.42% | 30,017 Cr | 5,552 Cr | |
| Abbott (this company) | ₹25,695.00 | 33.81 | 54,600 Cr | 11.44 | 2.52% | 32.51% | 41.87% | 7,295 Cr | 1,615 Cr |
| Median 11 companies | ₹1,953.60 | 33.81 | 1,07,413 Cr | 5.08 | 0.67% | 13.79% | 17.94% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
- Company has been maintaining a healthy dividend payout of 77.9%
Weaknesses
2- Stock is trading at 11.7 times its book value
- The company has delivered a poor sales growth of 9.96% over past five years.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
6 of 7 analysts rate Buy, 1 Hold, 0 Sell.
Updated 13 Oct 2026
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 29% · Jun 2026
AI Analysis — Bull vs Bear
As of the 2026-10-09 close, Abbott India Ltd traded at ₹26,000, giving a market capitalisation of ₹55,248.19 crore at a trailing P/E of 34.22 and a price-to-book of 11.57. The company has very little debt (debt-to-equity 0.04) and high returns (ROE 32.51%, ROCE 41.87%). Its 5-year sales CAGR is about 10%, while its 5-year profit CAGR is 17%. The stock is down 13% over one year and has compounded at only 4% a year over five years.
- The balance sheet carries almost no leverage. Debt-to-equity is 0.04, so interest costs and refinancing risk are minimal.
- Returns on capital are high and have held up over time. ROE is 32.51% and ROCE is 41.87%. ROE has averaged 31% over 10 years, 34% over 5 years and 35% over 3 years.
- Profit has grown much faster than sales. Profit CAGR is 17% over 5 years, 18% over 3 years and 20% over 10 years, against about 10% sales CAGR. This points to sustained margin expansion and operating leverage.
- Shareholder payouts are high. The dividend payout ratio is 77.9% and the dividend yield is 2.56%, which is relatively high for an Indian pharma company with a P/E of 34.22.
- Earnings are still growing faster than revenue in the latest period. TTM profit growth is 11% on TTM sales growth of 6%, giving trailing EPS of ₹759.88.
- The valuation multiple has compressed because the share price lagged earnings. The stock's 5-year CAGR of 4% trails the 5-year profit CAGR of 17%.
- The share price is about 15.2% below the 52-week high of ₹30,655 and about 3.4% above the 52-week low of ₹25,135, so much of the past year's decline is already reflected in the price.
- Long-term shareholder returns have been strong. The stock compounded at 19% a year over 10 years, which shows the business's record of creating value through cycles.
- The valuation is rich on book value. A P/B of 11.57 means the price assumes ROE stays above 30% for a long time, leaving little room for error if returns slip.
- Top-line growth is modest. The 5-year sales CAGR is about 10% (9.96%) and has slowed to 6% on a TTM basis, which is low for a stock on a trailing P/E of 34.22.
- Profit growth is slowing. TTM profit growth of 11% is below the 3-year CAGR of 18% and the 5-year CAGR of 17%, so the earnings acceleration that supported the multiple may be fading.
- Stock returns have been weak recently. The share price is down 13% over one year and has compounded at only 4% a year over both 3 and 5 years, well below the 19% 10-year CAGR.
- The earnings yield is low. A P/E of 34.22 implies an earnings yield of about 2.9%, which gives little valuation cushion if growth disappoints.
- ROE is edging down. Current ROE of 32.51% is below last year's 34% and the 3-year average of 35%, a possible early sign of pressure on returns.
- Profit growth has been driven by margins rather than volume. Profit grew 17% a year over 5 years against sales growth of about 10%. Further gains depend on margins widening again from already high levels (ROCE 41.87%), which is harder to keep up than revenue-led growth.
- Downside momentum is visible. At ₹26,000 the stock sits only about 3.4% above its 52-week low of ₹25,135, after falling about 15.2% from its 52-week high of ₹30,655.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Company Secretary Sangeeta Shetty resigns Sep 7
Abbott India Limited accepted the resignation of Sangeeta Shetty as Company Secretary and Compliance Officer, effective October 28, 2026. This is a routine governance change with no expected effect on operations or earnings.
TL;DR: The only recent news for Abbott India is the Company Secretary's resignation, a routine compliance-level change that doesn't signal anything about the business. These articles contain no information on earnings, product launches, pricing or regulatory matters, so they don't show whether things are getting better or worse. The main thing to watch is how smoothly the company names a new Company Secretary and Compliance Officer before October 28, 2026. Upcoming quarterly results and any drug price control (NLEM/DPCO) changes will matter more for the stock.
Analyst Forecasts
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Expenses | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 |
| Operating Profit | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 |
| OPM % | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% | 29% |
| Other Income | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 |
| Depreciation | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 |
| PBT | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% | 25% |
| Net Profit | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| EPS (₹) | 137 | 147 | 146 | 135 | 154 | 169 | 170 | 173 | 172 | 195 | 177 | 186 | 202 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 | 7,004 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 5,037 | 5,035 |
| Operating Profit | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,892 | 1,969 |
| OPM % | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% | 28% |
| Other Income | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 77 | 154 | 248 | 275 | 288 | 291 |
| Interest | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 25 | 25 |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 76 | 76 |
| PBT | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,079 | 2,158 |
| Tax % | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | 25% | — |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,552 | 1,615 |
| EPS (₹) | 108 | 120 | 130 | 189 | 212 | 279 | 325 | 376 | 447 | 565 | 666 | 730 | 760 |
| Div. Payout % | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% | 90% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 | 4,753 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | 172 |
| Other Liabilities | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | 1,556 |
| Total Liabilities | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
| Fixed Assets | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | 331 |
| CWIP | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | 6,165 |
| Total Assets | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 | 1,319 |
| Investing | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 | -371 |
| Financing | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 | -1,066 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 | -118 |
| Free Cash Flow | 199 | 226 | 287 | 180 | 504 | 611 | 704 | 904 | 860 | 1,165 | 960 | 1,307 |
| CFO/OP | 106 | 109 | 117 | 68 | 125 | 113 | 104 | 114 | 102 | 111 | 86 | 98 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 | 19 |
| Inventory Days | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 | 94 |
| Days Payable | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 | 109 |
| Cash Conversion Cycle | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 | 3 |
| Working Capital Days | 30 | 32 | 21 | 63 | 22 | 10 | 4 | -7 | -8 | -14 | 99 | 2 |
| ROCE % | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% | 45% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Abbott insights
61 extracted metrics + investor summaries across FY09–FY27.
Documents
Frequently Asked Questions about Abbott
What does Abbott India Ltd do?
Where is Abbott India Ltd (ABBOTINDIA) listed?
Which sector does Abbott India Ltd belong to?
What is the market capitalisation of Abbott India Ltd?
What is the PE ratio of Abbott India Ltd?
What is the 52-week high and low of Abbott India Ltd?
Does Abbott India Ltd pay dividends?
What is the Return on Equity (ROE) of Abbott India Ltd?
Company Information
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ABBOTINDIA.md for Abbott India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.